To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves abuse-deterrent labeling for Embeda

FDA approved expanded labeling for Embeda morphine sulfate/ naltrexone hydrochloride extended-release capsules from Pfizer Inc. (NYSE:PFE)

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE